-
公开(公告)号：EP3276004A3
公开(公告)日：2018-03-14
申请号：EP17190227.3
申请日：2010-06-07
申请人： Quark Pharmaceuticals, Inc. , The United States of America, as Represented by the Department of Veterans Affairs
IPC分类号： C12N15/113 , A61K31/7088
摘要： The present invention relates to oligonucleotide compounds for use in methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease chosen from p53 and CASP2; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.
-
公开(公告)号：EP3276004B1
公开(公告)日：2020-03-18
申请号：EP17190227.3
申请日：2010-06-07
申请人： Quark Pharmaceuticals, Inc. , The United States of America, as Represented by the Department of Veterans Affairs
IPC分类号： C12N15/113 , A61K31/7088
-
公开(公告)号：EP3276004A2
公开(公告)日：2018-01-31
申请号：EP17190227.3
申请日：2010-06-07
申请人： Quark Pharmaceuticals, Inc. , The United States of America, as Represented by the Department of Veterans Affairs
IPC分类号： C12N15/113 , A61K31/7088
摘要： The present invention relates to oligonucleotide compounds for use in methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease chosen from p53 and CASP2; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.
摘要翻译： 本发明涉及用于治疗慢性肾病（CKD）的方法中的寡核苷酸化合物，所述方法包括预防或延迟CKD发作的方法和预防CKD恶化和进展的方法。 在具体的实施方案中，本发明提供了用于治疗处于发生CKD风险的受试者的方法，其包括向所述受试者施用组合物，所述组合物包含a）治疗有效量的至少一种寡核苷酸化合物，其抑制与肾相关的人类靶基因的表达 选自p53和CASP2的疾病; 和b）药学上可接受的赋形剂或载体或其混合物，由此降低受试者中CKD的风险。
-
公开(公告)号：EP2440214A2
公开(公告)日：2012-04-18
申请号：EP10786615.4
申请日：2010-06-07
申请人： Quark Pharmaceuticals, Inc. , The United States of America, as Represented by the Department of Veterans Affairs
IPC分类号： A61K31/7088 , C07H21/02
CPC分类号： C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2310/321 , C12N2310/343 , C12N2310/3521
摘要： The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.
-
公开(公告)号：EP3149172B1
公开(公告)日：2018-07-18
申请号：EP15729289.7
申请日：2015-05-27
发明人： SQUIERS, Elizabeth C. , ERLICH, Shai , ROTHENSTEIN, Daniel , SHARON, Nir , ODENHEIMER, Daniel J. , FEINSTEIN, Elena
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1135 , A61K9/0019 , A61K31/713 , A61K45/06 , C12N2310/14 , C12N2310/317 , C12N2310/319 , C12N2310/321 , C12N2310/3515 , C12N2320/30 , C12N2310/3521
摘要： The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.
-
6.发明授权OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF ALOPECIA, ACUTE RENAL FAILURE AND OTHER DISEASES 有权寡核糖核苷酸及其使用用于治疗脱发的治疗方法，急性肾功能衰竭等病症
公开(公告)号：EP1799269B1
公开(公告)日：2016-09-07
申请号：EP05788492.6
申请日：2005-09-27
发明人： FEINSTEIN, Elena , ZURR, Daniel , EHRLICH, Shai
IPC分类号： C12N15/113 , A61K31/713 , C07H21/02 , A61P13/12 , A61P17/14 , A61P25/00 , A61P27/16
CPC分类号： C12N15/1135 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2320/30
-
7.发明公开METHODS AND COMPOSITIONS FOR TREATING DISEASES, DISORDERS OR INJURY OF THE NERVOUS SYSTEM 审中-公开方法和组合物以及对疾病，病症或神经系统病变的治疗
公开(公告)号：EP2776565A1
公开(公告)日：2014-09-17
申请号：EP12788061.5
申请日：2012-11-08
发明人： FEINSTEIN, Elena
IPC分类号： C12N15/113 , A61K31/713 , C07K16/40 , C07K16/18 , A61P25/00 , A61P27/00
CPC分类号： C12N15/1136 , A61K31/713 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12Y304/22055
摘要： Disclosed herein are compositions and methods of use thereof for treating diseases, disorders and injuries of the nervous system, com¬ prising a combination of a RTP801 or RTP801L inhibitor, and a Casp2 inhibitor.
-
公开(公告)号：EP2350279A2
公开(公告)日：2011-08-03
申请号：EP09748890.2
申请日：2009-10-22
发明人： FEINSTEIN, Elena , ALPERT, Evgenia , METT, Igor , BAR-ILAN, Amir , SPIVAK, Igor , KALINSKI, Hagar , SLAGER, Netanja
IPC分类号： C12N15/113 , A61K31/711
CPC分类号： C12N15/113 , A61K9/0048 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at 5 least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
-
公开(公告)号：EP2242854A2
公开(公告)日：2010-10-27
申请号：EP09702682.7
申请日：2009-01-14
发明人： FEINSTEIN, Elena , KALINSKI, Hagar , METT, Igor , ALPERT, EVGENIA
IPC分类号： C12Q1/68
CPC分类号： C12N15/113 , C12N2310/14 , C12N2320/11
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same and methods of use thereof for the inhibition of certain genes, including SOX9, ASPP1, CTSD, CAPNS1, FAS and FAS ligand. The compounds and compositions are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which gene expression has adverse consequences.
-
公开(公告)号：EP2137205A2
公开(公告)日：2009-12-30
申请号：EP08726066.7
申请日：2008-02-26
发明人： FEINSTEIN, Elena , SKALITER, Rami
CPC分类号： C07H21/02 , C12N15/1136 , C12N2310/11 , C12N2310/14
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.064 秒)
